The Impact of Abemaciclib in Treating HR-Positive HER2-Negative Breast Cancer

Hope Rugo, Professor of Medicine and Director of Breast Oncology, discusses the monarchE trial’s promising findings on the benefits of adding abemaciclib to standard endocrine therapy for high-risk early-stage HR-positive HER2-negative breast cancer, calling the results “extremely encouraging” for improving long-term survival rates.

This article is based on the MEDtalk Abemaciclib Shows Significant Benefit for HR-Positive HER2-Negative Patients with Advanced Breast Cancer with Hope S. Rugo.